The EEG Study Under Remimazolam Anesthesia in Children

Launched by SECOND AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial, called "The EEG Study Under Remimazolam Anesthesia in Children," is investigating how a medication called Remimazolam affects brain activity during anesthesia in children. Researchers want to understand the specific changes in brain waves, which can help doctors monitor how deeply a child is sedated while undergoing procedures. This study is important because it could improve how anesthesia is managed in young patients, making their experience safer and more effective.

To participate in this trial, children between the ages of 1 and 12 who are generally healthy (classified as ASA physical status I or II) and need Remimazolam for general anesthesia might be eligible. Parents or guardians must agree to let their child take part and sign a consent form. Participants will have their brain activity monitored during anesthesia, allowing researchers to gather important information about how Remimazolam works. If your child has certain health conditions or has been sick recently, they may not be able to join. Overall, this study aims to enhance the understanding of anesthesia in children, potentially leading to better care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. aged 1 years-12 years; 2, with American Society of Anesthesiologists (ASA) physical status I or II; 3, children requiring general anesthesia under remimazolam; 4, parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.
• Exclusion Criteria:
• • 1. Congenital malformation or other genetic conditions that are thought to affect brain development ;
• • 2. History of severe heart, brain, liver, kidney and metabolic diseases ;
• • 3. Premature infants (≤32 weeks);
• • 4. Upper respiratory tract infection in the last two weeks. -